- Home
- MCRI vs NRIX Comparison
MCRI vs NRIX Comparison
Compare MCRI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- NRIX
- Stock Information
- Founded
- MCRI 1972
- NRIX 2009
- Country
- MCRI United States
- NRIX United States
- Employees
- MCRI N/A
- NRIX N/A
- Industry
- MCRI Hotels/Resorts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- NRIX Health Care
- Exchange
- MCRI Nasdaq
- NRIX Nasdaq
- Market Cap
- MCRI 1.9B
- NRIX 728.6M
- IPO Year
- MCRI 1993
- NRIX 2020
- Fundamental
- Price
- MCRI $101.40
- NRIX $8.57
- Analyst Decision
- MCRI Hold
- NRIX Strong Buy
- Analyst Count
- MCRI 5
- NRIX 14
- Target Price
- MCRI $96.20
- NRIX $29.07
- AVG Volume (30 Days)
- MCRI 88.0K
- NRIX 786.7K
- Earning Date
- MCRI 10-22-2025
- NRIX 10-10-2025
- Dividend Yield
- MCRI 1.17%
- NRIX N/A
- EPS Growth
- MCRI N/A
- NRIX N/A
- EPS
- MCRI 4.22
- NRIX N/A
- Revenue
- MCRI $534,693,999.00
- NRIX $88,381,000.00
- Revenue This Year
- MCRI $6.87
- NRIX $74.59
- Revenue Next Year
- MCRI $4.19
- NRIX N/A
- P/E Ratio
- MCRI $24.29
- NRIX N/A
- Revenue Growth
- MCRI 4.65
- NRIX 41.86
- 52 Week Low
- MCRI $69.99
- NRIX $8.18
- 52 Week High
- MCRI $113.88
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- MCRI 48.09
- NRIX 36.45
- Support Level
- MCRI $100.20
- NRIX $8.33
- Resistance Level
- MCRI $104.53
- NRIX $10.13
- Average True Range (ATR)
- MCRI 2.36
- NRIX 0.50
- MACD
- MCRI -0.46
- NRIX -0.03
- Stochastic Oscillator
- MCRI 18.32
- NRIX 13.33
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.